Analysis of the Intracellular Localization of P73 N-terminal Protein Isoforms TAp73 and ∆Np73 in Medulloblastoma Cell Lines

Overview

Journal J Mol Histol

Specialty Biochemistry

Date 2010 Aug 31

PMID 20803057

Citations 5

Authors

Marta Nekulova

Karel Zitterbart

Jaroslav Sterba

Renata Veselska

Affiliations

Soon will be listed here.

Abstract

The protein homologous to the tumor suppressor p53, p73, has essential roles in development and tumorigenesis. This protein exists in a wide range of isoforms with different, even antagonistic, functions. However, there are virtually no detailed morphological studies analyzing the endogenous expression of p73 isoforms at the cellular level in cancer cells. In this study, we investigated the expression and subcellular distribution of two N-terminal isoforms, TAp73 and ΔNp73, in medulloblastoma cells using immunofluorescence microscopy. Both proteins were observed in all cell lines examined, but differences were noted in their intracellular localization between the reference Daoy cell line and four newly established medulloblastoma cell lines (MBL-03, MBL-06, MBL-07 and MBL-10). In the new cell lines, TAp73 and ΔNp73 were located predominantly in cell nuclei. However, there was heterogeneity in TAp73 distribution in the cells of all MBL cell lines, with the protein located in the nucleus and also in a limited non-random area in the cytoplasm. In a small percentage of cells, we detected cytoplasmic localization of TAp73 only, i.e., nuclear exclusion was observed. Our results provide a basis for future studies on the causes and function of distinct intracellular localization of p73 protein isoforms with respect to different protein-protein interactions in medulloblastoma cells.

Citing Articles

Mechanisms of Functional Pleiotropy of p73 in Cancer and Beyond.

Logotheti S, Richter C, Murr N, Spitschak A, Marquardt S, Putzer B Front Cell Dev Biol. 2021; 9:737735.

PMID: 34650986 PMC: 8506118. DOI: 10.3389/fcell.2021.737735.

NPI-0052 and γ-radiation induce a synergistic apoptotic effect in medulloblastoma.

Frisira E, Rashid F, Nath Varma S, Badodi S, Benjamin-Ombo V, Michod D Cell Death Dis. 2019; 10(11):785.

PMID: 31619667 PMC: 6795856. DOI: 10.1038/s41419-019-2026-y.

Overexpression of the ∆Np73 isoform is associated with centrosome amplification in brain tumor cell lines.

Mikulenkova E, Neradil J, Zitterbart K, Sterba J, Veselska R Tumour Biol. 2015; 36(10):7483-91.

PMID: 25910708 DOI: 10.1007/s13277-015-3474-3.

Mechanisms, function and clinical applications of DNp73.

Di C, Yang L, Zhang H, Ma X, Zhang X, Sun C Cell Cycle. 2013; 12(12):1861-7.

PMID: 23708520 PMC: 3735700. DOI: 10.4161/cc.24967.

A novel dual signaling axis for NSP 5a3a induced apoptosis in head and neck carcinoma.

DAgostino L, Giordano A Oncotarget. 2011; 2(12):1055-74.

PMID: 22170762 PMC: 3282067. DOI: 10.18632/oncotarget.306.

References

Dominguez G, Pena C, Silva J, Garcia J, Garcia V, Rodriguez R . The presence of an intronic deletion in p73 and high levels of ZEB1 alter the TAp73/DeltaTAp73 ratio in colorectal carcinomas. J Pathol. 2006; 210(4):390-7. DOI: 10.1002/path.2066. View

Castellino R, De Bortoli M, Lin L, Skapura D, Rajan J, Adesina A . Overexpressed TP73 induces apoptosis in medulloblastoma. BMC Cancer. 2007; 7:127. PMC: 1955450. DOI: 10.1186/1471-2407-7-127. View

Stiewe T, Zimmermann S, Frilling A, Esche H, Putzer B . Transactivation-deficient DeltaTA-p73 acts as an oncogene. Cancer Res. 2002; 62(13):3598-602. View

De Laurenzi V, Catani M, Terrinoni A, Corazzari M, Melino G, Costanzo A . Additional complexity in p73: induction by mitogens in lymphoid cells and identification of two new splicing variants epsilon and zeta. Cell Death Differ. 1999; 6(5):389-90. DOI: 10.1038/sj.cdd.4400521. View

Tannapfel A, Wasner M, Krause K, Geissler F, Katalinic A, Hauss J . Expression of p73 and its relation to histopathology and prognosis in hepatocellular carcinoma. J Natl Cancer Inst. 1999; 91(13):1154-8. DOI: 10.1093/jnci/91.13.1154. View

Di Vinci A, Sessa F, Casciano I, Banelli B, Franzi F, Brigati C . Different intracellular compartmentalization of TA and DeltaNp73 in non-small cell lung cancer. Int J Oncol. 2009; 34(2):449-56. View

Tanaka Y, Ota K, Kameoka M, Itaya A, Yoshihara K . Up-regulation of NFkappaB-responsive gene expression by DeltaNp73alpha in p53 null cells. Exp Cell Res. 2006; 312(8):1254-64. DOI: 10.1016/j.yexcr.2005.12.013. View

Tannapfel A, John K, Mise N, Schmidt A, Buhlmann S, Ibrahim S . Autonomous growth and hepatocarcinogenesis in transgenic mice expressing the p53 family inhibitor DNp73. Carcinogenesis. 2007; 29(1):211-8. DOI: 10.1093/carcin/bgm236. View

Ishimoto O, Kawahara C, Enjo K, Obinata M, Nukiwa T, Ikawa S . Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73. Cancer Res. 2002; 62(3):636-41. View

10.

Goldschneider D, Million K, Meiller A, Haddada H, Puisieux A, Benard J . The neurogene BTG2TIS21/PC3 is transactivated by DeltaNp73alpha via p53 specifically in neuroblastoma cells. J Cell Sci. 2005; 118(Pt 6):1245-53. DOI: 10.1242/jcs.01704. View

11.

Watson I, Blanch A, Lin D, Ohh M, Irwin M . Mdm2-mediated NEDD8 modification of TAp73 regulates its transactivation function. J Biol Chem. 2006; 281(45):34096-103. DOI: 10.1074/jbc.M603654200. View

12.

Sayan A, Paradisi A, Vojtesek B, Knight R, Melino G, Candi E . New antibodies recognizing p73: comparison with commercial antibodies. Biochem Biophys Res Commun. 2005; 330(1):186-93. DOI: 10.1016/j.bbrc.2005.02.145. View

13.

Herms J, Neidt I, Luscher B, Sommer A, Schurmann P, Schroder T . C-MYC expression in medulloblastoma and its prognostic value. Int J Cancer. 2000; 89(5):395-402. View

14.

Veselska R, Kuglik P, Cejpek P, Svachova H, Neradil J, Loja T . Nestin expression in the cell lines derived from glioblastoma multiforme. BMC Cancer. 2006; 6:32. PMC: 1403792. DOI: 10.1186/1471-2407-6-32. View

15.

Kim K, Kim T, Kang K, Choi K . Amphiphysin IIb-1, a novel splicing variant of amphiphysin II, regulates p73beta function through protein-protein interactions. Oncogene. 2001; 20(46):6689-99. DOI: 10.1038/sj.onc.1204839. View

16.

Wang J, Liu Y, Hande M, Wong A, Jin Y, Yin Y . TAp73 is a downstream target of p53 in controlling the cellular defense against stress. J Biol Chem. 2007; 282(40):29152-62. DOI: 10.1074/jbc.M703408200. View

17.

Beitzinger M, Hofmann L, Oswald C, Beinoraviciute-Kellner R, Sauer M, Griesmann H . p73 poses a barrier to malignant transformation by limiting anchorage-independent growth. EMBO J. 2008; 27(5):792-803. PMC: 2265751. DOI: 10.1038/emboj.2008.13. View

18.

Hu Y, Lehrach H, Janitz M . Comparative analysis of an experimental subcellular protein localization assay and in silico prediction methods. J Mol Histol. 2009; 40(5-6):343-52. PMC: 2834777. DOI: 10.1007/s10735-009-9247-9. View

19.

Tophkhane C, Yang S, Zhao Z, Yang X . Cell density-dependent regulation of p73 in breast cancer cells. Int J Oncol. 2009; 35(6):1429-34. DOI: 10.3892/ijo_00000461. View

20.

De Laurenzi V, Costanzo A, Barcaroli D, Terrinoni A, Falco M, Annicchiarico-Petruzzelli M . Two new p73 splice variants, gamma and delta, with different transcriptional activity. J Exp Med. 1998; 188(9):1763-8. PMC: 2212516. DOI: 10.1084/jem.188.9.1763. View